The colorectal cancer stem-like cell hypothesis: A pathologist's point of view

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 230-236

  Susman, S ^a,b   Tomuleasa, Ciprian ^a,c   Soritau, O ^a   Mihu, C ^b   Rus Ciuca, D ^a   Sabourin, J C ^d   Bibeau, F ^e   Irimie, A ^a,b   Buiga, R ^a  

^a Ion Chiricuta Comprehensive Cancer Center   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HÔPITAL CHARLES NICOLLE   (France)

^e CENTRE VAL D AURELLE   (France)

Author keywords

Cancer stem like cells; Colon carcinogenesis; Colorectal cancer

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; BEVACIZUMAB; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; CANCER GROWTH FACTOR; CD133 ANTIGEN; CD24 ANTIGEN; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; FOLINIC ACID; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR 54; HERMES ANTIGEN; IRINOTECAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN ASSOCIATED PROTEIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLERIXAFOR; PROTEIN P53; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNINDEXED DRUG; WNT PROTEIN;

ADENOMATOUS POLYP; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PATIENT; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CRYPT CELL; EMBRYO DEVELOPMENT; ENDODERM; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GASTROINTESTINAL DYSPLASIA; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM; LIVER METASTASIS; MYOFIBROBLAST; ONCOGENE K RAS; OXIDATIVE STRESS; PANETH CELL; PATHOLOGIST; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEM CELL NICHE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; COLORECTAL TUMOR; FEMALE; MALE; PATHOLOGY;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASTIC STEM CELLS;

EID: 84864388026     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Parkin DM. International variation. Oncogene 2004; 23: 6329-6340. (Pubitemid 39272833)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. Melissa M, Ahmedin J, Elizabeth W. International Trends in Colorectal Cancer Incidence Rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-1694.
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
5. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of Fc {gamma} RIIa-Fc {gamma} RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
6. Lenz HJ. First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. Cancer Treat Rev 2008; 34(Suppl 2): S3-S7.
7. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005; 1044: 1-5. (Pubitemid 40967588)
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110. (Pubitemid 46067310)
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115. (Pubitemid 46067311)
10. Jones S, Chen WD, Pirmigiani G et al. Comparative lesion sequencing provides insights into tumor evolution Proc Natl Acad Sci U S A 2008; 105: 4283-4288. (Pubitemid 351754372)
11. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000; 190: 412-416. (Pubitemid 30163579)
12. Scoville DH, Sato T, He XC et al. Current view: Intestinal stem cells and signaling. Gastroenterology 2008; 134: 849-864. (Pubitemid 351312767)
13. Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut 2004; 53: 899-910. (Pubitemid 38662143)
14. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19: 877-890. (Pubitemid 40548056)
15. Roberts DJ. Molecular mechanisms of development of the gastrointestinal tract. Dev Dyn 2000; 219: 109-120.
16. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet 2004; 5: 691-701. (Pubitemid 39150127)
17. He XC, Zhang J, Tong WG et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004; 36: 1117-1121. (Pubitemid 41184475)
18. Schonhoff SE, Giel-Moloney M, Leiter AB. Mini review: Development and differentiation of gut endocrine cells. Endocrinology 145: 2639-2644.
19. van Es JH, Jay P, Gregorieff A et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol 2005; 7: 381-386. (Pubitemid 40533127)
20. Shroyer NF, Wallis D, Venken KJ, Bellen HJ, Zoghbi HY. Gfi1 functions downstream of Math1 to control intestinal secretory cell subtype allocation and differentiation. Genes Dev 2005; 19: 2412-2417. (Pubitemid 41483688)
21. Brittan M, Wright NA. Gastrointestinal stem cells. J Pathol 2002; 197: 492-509.
22. Lipkin M, Bell B, Sherlock P. Cell proliferation kinetics in the gastrointestinal tract of man. i. cell renewal in colon and rectum. J Clin Invest 1963; 42: 767-776.
23. Potten CS, Booth C, Tudor GL et al. Identification of a putative intestinal stem cell and early lineage marker musashi-1. Differentiation 2003; 71: 28-41. (Pubitemid 38230417)
24. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010; 138: 2151-2162.
25. Barker N, van Es JH, Kuipers J et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007. (Pubitemid 350014593)
26. Sato T, Vries RG, Snippert HJ et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
27. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40: 915-920. (Pubitemid 351913652)
28. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010 29; 327(5965): 542-545.
29. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008; 26: 630-637.
30. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009; 71: 241-260.
31. Sikandar SS, Pate KT, Anderson S et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010; 70: 1469-1478.
32. Mills JC, Gordon JI. The intestinal stem cell niche: There grows the neighborhood. Proc Natl Acad Sci USA 2001; 98: 12334-12336. (Pubitemid 33019942)
33. Massague J, Blain SW, Lo RS. TGF signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
34. Batlle E, Henderson JT, Beghtel H et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263. (Pubitemid 35292445)
35. van de Wetering M, Sancho E, Verweij C et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250. (Pubitemid 35292444)
36. Vermeulen L, De Sousa E Melo F, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476.
37. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
38. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2000; 127: 469-480.
39. Roose J, Molenaar M, Peterson J et al. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998; 395: 608-612. (Pubitemid 28475715)
40. Hallikas O, Palta K, Sinjushina N et al. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell 2006; 124: 47-59. (Pubitemid 43069309)
41. McKenna LB, Schug J, Vourekas A et al. MicroRNAs Control Intestinal Epithelial Differentiation, Architecture, and Barrier Function. Gastroenterology 2010; 139: 1654-1664.
42. Yamashita YM, Fuller MT, Jones DL. Signaling in stem cell niches: lessons from the Drosophila germline. J Cell Sci 2005; 118 (Pt 4): 665-672. (Pubitemid 40372576)
43. Xie T, Spradling AC. A niche maintaining germ line stem cells in the Drosophila ovary. Science 2000; 290 (5490): 328-330.
44. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science 2000; 287 (5457): 1427-1430. (Pubitemid 30127126)
45. Kim KM, Shibata D. Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene 2002; 21: 5441-5449. (Pubitemid 34983480)
46. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer 2008; 8: 415-424. (Pubitemid 351744961)
47. Campbell F, Williams GT, Appleton MA, Dixon MF, Harris M, Williams ED. Post-irradiation somatic mutation and clonal stabilisation time in the human colon. Gut 1996; 39: 569-573. (Pubitemid 26376041)
48. Greaves LC, Preston SL, Tadrous PJ et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA 2006; 103: 714-719. (Pubitemid 43153091)
49. Park HS, Goodlad RA, Wright NA. Crypt fission in the small intestine and colon. A mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. Am J Pathol 1995; 147: 1416-1427.
50. Totafurno J, Bjerknes M, Cheng H. The crypt cycle. Crypt and villus production in the adult intestinal epithelium. Biophys J 1987; 52: 279-294.
51. Wasan HS, Park HS, Liu KC et al. APC in the regulation of intestinal crypt fission. J Pathol 1998; 185: 246-255. (Pubitemid 28320045)
52. Paulsen JE, Steffensen IL, Løberg EM, Husøy T, Namork E, Alexander J. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 2001; 61: 5010-5015. (Pubitemid 32681528)
53. Preston SL, Wong WM, Chan AO et al. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003; 63: 3819-3825. (Pubitemid 36793072)
54. Wong WM, Mandir N, Goodlad RA et al. Histogenesis of human colorectal adenomas and hyperplastic polyps: the role of cell proliferation and crypt fission. Gut 2002; 50: 212-217. (Pubitemid 34087934)
55. Brabletz T, Jung A, Reu S et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001; 98: 10356-10361. (Pubitemid 32803024)
56. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749. (Pubitemid 41486367)
57. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007; 67: 1979-1987. (Pubitemid 46424214)
58. Tomlinson I, Ilyas M, Johnson V et al. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer. J Pathol 1998; 184: 148-152. (Pubitemid 28088422)
59. Ahuja N, Mohan AL, Li Q et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57: 3370-3374. (Pubitemid 27355477)
60. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123: 862-876. (Pubitemid 34977092)
61. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008; 15: 947-958. (Pubitemid 351712600)
62. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer sternness and malignant behavior. Curr Opta Cell Biol 2007; 19: 150-158. (Pubitemid 46386404)
63. Vermeulen L, De Sousa E Melo F, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476.
64. Odoux C, Fohrer H, Hoppo T et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008; 68: 6932-6941.
65. Sottoriva A, Verhoeff JJ, Borovski T et al. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 2010; 70: 46-56.
66. Johnsen HE, Kjeldsen MK, Urup T et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer 2009; 45 (Suppl 1): 194-201.
67. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer 2010; 103: 439-445.
68. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
69. Yang AD, Fan F, Camp ER et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12(14 Pt 1): 4147-4153.
70. Spadema S, Schmalhofer O, Wahlbuhl M et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008; 68: 537-544. (Pubitemid 351380082)
71. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833-3839. (Pubitemid 36793074)
72. Kim J, Takeuchi H, Lam ST et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-2753. (Pubitemid 46179464)
73. Schimanski CC, Schwald S, Simiantonaki N et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005; 11: 1743-1750. (Pubitemid 40471835)
74. Maw MA, Corbeil D, Koch J et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000; 9: 27-34. (Pubitemid 30145285)
75. Miraglia S, Godfrey W, Yin AH et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021. (Pubitemid 28007218)
76. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402. (Pubitemid 47506537)
77. Artells R, Moreno I, Díaz T et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010; 46: 642-649.
78. Saigusa S, Tanaka K, Toiyama Y et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009; 16: 3488-3498.
79. Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol 2010; 222: 335-344.
80. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-3389.
81. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010; 107: 3722-3727.
82. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
83. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
84. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128: 509-518.